Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 18/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 17/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.42 |
| ▸ | CDK2 | P24941 | 10/20 | 0.42 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973206 | 0.74 | CDC7 (0.62) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL6804853 | 0.74 | CDC7 (0.62) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL11973008 | 0.71 | GRM5 (0.31) | — | |
| SCHEMBL15605993 | 0.65 | GRM5 (0.36) | ROCK1 | |
| SCHEMBL614677 | 0.65 | CDC7 (1.00) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL11973038 | 0.64 | CDC7 (0.36) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL31684595 | 0.63 | CDC7 (0.38) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL611741 | 0.62 | CDC7 (0.66) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL12699016 | 0.62 | CDC7 (0.34) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL7484888 | 0.61 | ROCK2 (0.42) | CDC7ROCK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2627181-A2 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012051410-A2 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012051410-A2 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | CDC7 1355/4885DBF4 3209/4885ROCK1 201/4885 |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | CDC7 1355/4885DBF4 3209/4885ROCK1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.